Ipca Laboratories Ltd.

₹1,488.3

-19.9 (-1.3%)

IPCALAB Share Price

Pharmaceuticals & Biotechnology

As on April 2, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 37,584 Cr

P/E Ratio51.18

Dividend Yield0.27 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	1,550.74	Bearish
10-DMA	1,544.73	Bearish
20-DMA	1,534.5	Bearish
50-DMA	1,494.69	Bearish
100-DMA	1,465.84	Bullish
200-DMA	1,419.04	Bullish

Historical Performance

1 Year

5.1%

3 Years

83.7%

5 Years

58.2%

10 Years

420.7%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	88,968	76,624	62,043	57,967	53,949
Total Expenditure	72,263	63,984	53,010	45,391	39,137
Other Income	1,513	1,844	1,518	1,217	1,292
Operating Profit	18,218	14,484	10,550	13,793	16,104
Interest	878	1,408	482	112	123
Depreciation	3,978	3,572	2,616	2,324	2,092
Profit Before Tax	11,311	8,427	7,453	11,357	13,890
Consolidated Net Profit	7,377	5,473	4,713	8,841	11,400
Adjusted EPS	29	22	19	35	45

Compounded Sales Growth

10 Years:23.1

5 Years:14

3 Years:8.9

TTM:3

Compounded Profit Growth

10 Years:23.7

5 Years:4

3 Years:-3.6

TTM:6.2

Stock Price CAGR

10 Years:17.9

5 Years:9.6

3 Years:22.5

TTM:-0.6

Return on Equity

10 Years:3.7

5 Years:44.9

3 Years:18.6

last year:29.1

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	254	254	254	254	254
Total Reserves	69,204	63,052	58,166	54,395	46,763
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	9,691	10,144	9,017	6,139	1,897
Other Current Liabilities	7,255	7,326	4,881	4,205	2,045
Short Term Borrowings	4,952	5,592	6,618	3,678	1,766
Total Liabilities	1,17,436	1,10,970	86,229	76,215	60,664
Capital Work in Progress	6,162	3,236	1,222	2,939	1,837
Long Term Loans & Advances	3,173	3,156	2,296	1,696	1,856
Currents Investments	7,634	5,584	3,233	7,193	3,938
Short Term Loans and Advances	3,049	1,975	1,556	2,018	1,932
Total Current Assets	59,670	55,355	51,893	44,467	34,370
Total Assets	1,17,436	1,10,970	86,229	76,215	60,664
Adjusted Book Value	274	250	230	215	185

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 51.18, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 22.5%, indicating sustained price appreciation.
The stock carries a low beta of 0.3, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹18218 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹88968 million, indicating a large and established business.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 993790.1

No. of Shares: 668 (Approx)

Performance:-0.6%

P/L: ₹-6209.9

NIFTY Performance: -2.3%

1 day Top Gainers